Malignant mesothelioma (MM) is an aggressive malignancy, highly resistant to current medical and surgical therapies, whose tumor cells characteristically show a high level of aneuploidy and genomic instability. We tested our hypothesis that targeting chromosomal instability in MM would improve response to therapy. Thr/Tyr kinase (TTK)/monopolar spindle 1 kinase (Mps-1) is a kinase of the spindle assembly checkpoint that controls cell division and cell fate. CFI-402257 is a novel, selective inhibitor of Mps-1 with antineoplastic activity. We found that CFI-402257 suppresses MM growth. We found that Mps-1 is overexpressed in MM and that its expression correlates with poor patients’ outcome. In vitro, CFI-402257-mediated inhibition of Mps-1 resulted in abrogation of the mitotic checkpoint, premature progression through mitosis, marked aneuploidy and mitotic catastrophe. In vivo, CFI-402257 reduced MM growth in an orthotopic, syngeneic model, when used as a single agent, and more so when used in combination with cisplatin+pemetrexed, the current standard of care. Our preclinical findings indicate that CFI-402257 is a promising novel therapeutic agent to improve the efficacy of the current chemotherapeutic regimens for MM patients.
Subscribe to Journal
Get full journal access for 1 year
only $9.98 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
monopolar spindle 1
dual specificity Thr/Tyr kinase.
Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012; 227: 44–58.
Henley SJ, Larson TC, Wu M, Antao VC, Lewis M, Pinheiro GA et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health 2013; 19: 1–10.
Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T . Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011; 89: 716–724,24A-24C.
Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D et al. Consensus report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol 2016; 11: 1246–1262.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–2644.
Isobe H, Wellham L, Sauerteig A, Sridhar KS, Ramachandran C, Krishan A . Doxorubicin retention and chemoresistance in human mesothelioma cell lines. Int J Cancer 1994; 57: 581–585.
Comertpay S, Pastorino S, Tanji M, Mezzapelle R, Strianese O, Napolitano A et al. Evaluation of clonal origin of malignant mesothelioma. J Transl Med 2014; 12: 301.
Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 2015; 75: 264–269.
Singhi AD, Krasinskas AM, Choudry HA, Bartlett DL, Pingpank JF, Zeh HJ et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol 2016; 29: 14–24.
Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol 2015; 10: 492–499.
Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 2016; 48: 407–416.
Ugurluer G, Chang K, Gamez ME, Arnett AL, Jayakrishnan R, Miller RC et al. Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma. Anticancer Res 2016; 36: 2331–2338.
Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 2015; 10: 565–576.
Hagemeijer A, Versnel MA, Van Drunen E, Moret M, Bouts MJ, van der Kwast TH et al. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 1990; 47: 1–28.
Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR . Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993; 53: 4349–4355.
Zeiger MA, Gnarra JR, Zbar B, Linehan WM, Pass HI . Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. Genes Chromosomes Cancer 1994; 11: 15–20.
Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K et al. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 2007; 98: 438–446.
Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T et al. High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proc Natl Acad Sci USA 2016; 113: 13432–13437.
Jean D, Thomas E, Manie E, Renier A, de Reynies A, Lecomte C et al. Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol 2011; 178: 881–894.
Napolitano A, Pellegrini L, Dey A, Larson D, Tanji M, Flores EG et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 2016; 35: 1996–2002.
Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012; 72: 3290–3301.
Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ et al. Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci 2010; 1203: 7–14.
Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43: 1022–1025.
Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D et al. Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700 s. PLoS Genet 2015; 11: e1005633.
Gazdar AF, Carbone M . Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 2003; 5: 177–181.
Carbone M . Simian virus 40 and human tumors: It is time to study mechanisms. J Cell Biochem 1999; 76: 189–193.
Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M et al. Germline BAP1 mutations induce a Warburg effect. Cell Death Differ 2017, epub ahed of print 30 June 2017 doi:10.1038/cdd.2017.95.
Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M et al. BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature 2017; 546: 549–553.
Kops GJ, Weaver BA, Cleveland DW . On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5: 773–785.
Holland AJ, Cleveland DW . Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 2009; 10: 478–487.
Stucke VM, Sillje HH, Arnaud L, Nigg EA . Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. EMBO J 2002; 21: 1723–1732.
Liu X, Winey M . The MPS1 family of protein kinases. Annu Rev Biochem 2012; 81: 561–585.
Nijenhuis W, von Castelmur E, Littler D, De Marco V, Tromer E, Vleugel M et al. A TPR domain-containing N-terminal module of MPS1 is required for its kinetochore localization by Aurora B. J Cell Biol 2013; 201: 217–231.
Ji Z, Gao H, Yu H . Cell division cycle. Kinetochore attachment sensed by competitive Mps1 and microtubule binding to Ndc80C. Science 2015; 348: 1260–1264.
Jelluma N, Brenkman AB, van den Broek NJ, Cruijsen CW, van Osch MH, Lens SM et al. Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment. Cell 2008; 132: 233–246.
Fisk HA, Mattison CP, Winey M . A field guide to the Mps1 family of protein kinases. Cell Cycle 2004; 3: 439–442.
Fisk HA, Mattison CP, Winey M . Human Mps1 protein kinase is required for centrosome duplication and normal mitotic progression. Proc Natl Acad Sci USA 2003; 100: 14875–14880.
Wei JH, Chou YF, Ou YH, Yeh YH, Tyan SW, Sun TP et al. TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68. J Biol Chem 2005; 280: 7748–7757.
Ling Y, Zhang X, Bai Y, Li P, Wei C, Song T et al. Overexpression of Mps1 in colon cancer cells attenuates the spindle assembly checkpoint and increases aneuploidy. Biochem Biophys Res Commun 2014; 450: 1690–1695.
Daniel J, Coulter J, Woo JH, Wilsbach K, Gabrielson E . High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci USA 2011; 108: 5384–5389.
Kwiatkowski N, Jelluma N, Filippakopoulos P, Soundararajan M, Manak MS, Kwon M et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol 2010; 6: 359–368.
Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P et al. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 2010; 70: 10255–10264.
Jemaa M, Galluzzi L, Kepp O, Senovilla L, Brands M, Boemer U et al. Characterization of novel MPS1 inhibitors with preclinical anticancer activity. Cell Death Differ 2013; 20: 1532–1545.
Tardif KD, Rogers A, Cassiano J, Roth BL, Cimbora DM, McKinnon R et al. Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1. Mol Cancer Ther 2011; 10: 2267–2275.
Janssen A, Kops GJ, Medema RH . Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci USA 2009; 106: 19108–19113.
Mason J, Wei X, Fletcher G, Kiarash R, Brokx R, Hodgson R et al. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci USA 2017; 114: 3127–3132.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D'Amico TA et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res 2015; 196: 23–32.
Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006; 103: 10397–10402.
Goto H, Tomono Y, Ajiro K, Kosako H, Fujita M, Sakurai M et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J Biol Chem 1999; 274: 25543–25549.
Liu Y, Laufer R, Patel NK, Ng G, Sampson PB, Li SW et al. Discovery of pyrazolo[1,5-a]pyrimidine TTK inhibitors: CFI-402257 is a potent, selective, bioavailable anticancer agent. ACS Med Chem Lett 2016; 7: 671–675.
Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G . Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23: 2825–2837.
Mezzapelle R, Rrapaj E, Gatti E, Ceriotti C, Marchis FD, Preti A et al. Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Sci Rep 2016; 6: 22850.
van Jaarsveld RH, Kops GJPL . Difference makers: chromosomal instability versus aneuploidy in cancer. Trends Cancer 2016; 2: 561–571.
Cohen P . Protein kinases–the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002; 1: 309–315.
Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, Williams SA et al. Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One 2012; 7: e46091.
Napolitano A, Antoine DJ, Pellegrini L, Baumann F, Pagano I, Pastorino S et al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res 2016; 22: 3087–3096.
Hao JQ, Li Q, Xu SP, Shen YX, Sun GY . Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro. Chin Med J (Engl) 2008; 121: 602–607.
This work was supported in part by the NCI-R01 CA198138 to MC; by the NCI-R01 CA160715 to HY; and by the University of Hawai’i Foundation, which received an unrestricted gift to support MM research from Honeywell International Inc., to MC; and from United-4-a-Cure, to MC and HY CFI-402257 was synthesized and provided by our collaborators and co-authors at the Campbell Family Institute for Breast Cancer Research, Toronto, Canada.
MC provides consultation for mesothelioma diagnosis. All other authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in, or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Supplementary Information accompanies this paper on the Oncogene website
About this article
Cite this article
Szymiczek, A., Carbone, M., Pastorino, S. et al. Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma. Oncogene 36, 6501–6507 (2017). https://doi.org/10.1038/onc.2017.266
BioMed Research International (2020)
Journal of Cancer Research and Clinical Oncology (2019)
Experimental Cell Research (2019)
Journal of Thoracic Oncology (2018)